NMU Is a Poor Prognostic Biomarker in Patients with Lung Adenocarcinoma

Figure 1

The expression of NMU in patients with LUAD. (a) The expression of NMU in LUAD as evaluated in the UALCAN database ( vs. normal). (b) The expression of NMU in LUAD, evaluated using the GEPIA online tool ( vs. normal, T: tumor; N: normal). (c) Expression of NMU in LUAD based on race ( vs. Asian group, vs. normal), (d) individual cancer grade ( vs. normal), (e) patient’s smoking habits ( vs. nonsmoker), and (f) TP53 mutation status ( vs. nonmutation).

(a)

(b)

(c)

(d)

(e)

(f)